RATIONALE: Surfactant protein D (SP-D) is a member of the collectin family of soluble, innate, host defense molecules with demonstrated immunomodulatory properties in vitro. Constitutive absence of SP-D in mice is associated with lung inflammation, alteration in surfactant lipid homeostasis, and increased oxidative-nitrative stress. OBJECTIVES: To test the hypothesis that SP-D would protect against acute lung injury from hyperoxia in vivo. METHODS: Transgenic mice overexpressing rat SP-D constitutively (SP-D OE) or conditionally via regulation with doxycycline (SP-D Dox-on) were subjected to continuous hyperoxic challenge for up to 14 days. MEASUREMENTS AND MAIN RESULTS: Compared with littermate control mice (wild-type [WT]), SP-D OE mice exposed to 80% O(2) demonstrated substantially increased survival accompanied by significant reductions in wet to dry lung ratios and bronchoalveolar lavage (BAL) protein. Although SP-D OE and WT mice exhibited a twofold increase in total BAL cells and neutrophilia in response to hyperoxia, the SP-D OE group had lower levels of BAL proinflammatory cytokines and chemokines, including IL-6, tumor necrosis factor-alpha, and monocyte chemotactic protein-1; increased mRNA levels of the transcription factor NF-E2 related factor-2 (NRF-2) and phase 2 antioxidants hemoxygenase-1 (HO-1), glutathione peroxidase-2 (GPx-2) and NAD(P)H quinone oxidoreductase-1 (Nqo-1); and decreases in lung tissue thiobarbituric acid-reactive substances. As proof of principle, the protective role of SP-D on hyperoxic injury was confirmed as SP-D Dox-on mice exposed to 85% O(2) demonstrated increased mortality upon withdrawal of doxycycline. CONCLUSIONS: Local expression of SP-D protects against hyperoxic lung injury through modulation of proinflammatory cytokines and antioxidant enzymatic scavenger systems.
RATIONALE: Surfactant protein D (SP-D) is a member of the collectin family of soluble, innate, host defense molecules with demonstrated immunomodulatory properties in vitro. Constitutive absence of SP-D in mice is associated with lung inflammation, alteration in surfactant lipid homeostasis, and increased oxidative-nitrative stress. OBJECTIVES: To test the hypothesis that SP-D would protect against acute lung injury from hyperoxia in vivo. METHODS:Transgenic mice overexpressing ratSP-D constitutively (SP-D OE) or conditionally via regulation with doxycycline (SP-DDox-on) were subjected to continuous hyperoxic challenge for up to 14 days. MEASUREMENTS AND MAIN RESULTS: Compared with littermate control mice (wild-type [WT]), SP-D OE mice exposed to 80% O(2) demonstrated substantially increased survival accompanied by significant reductions in wet to dry lung ratios and bronchoalveolar lavage (BAL) protein. Although SP-D OE and WT mice exhibited a twofold increase in total BAL cells and neutrophilia in response to hyperoxia, the SP-D OE group had lower levels of BAL proinflammatory cytokines and chemokines, including IL-6, tumor necrosis factor-alpha, and monocyte chemotactic protein-1; increased mRNA levels of the transcription factor NF-E2 related factor-2 (NRF-2) and phase 2 antioxidants hemoxygenase-1 (HO-1), glutathione peroxidase-2 (GPx-2) and NAD(P)H quinone oxidoreductase-1 (Nqo-1); and decreases in lung tissue thiobarbituric acid-reactive substances. As proof of principle, the protective role of SP-D on hyperoxic injury was confirmed as SP-DDox-on mice exposed to 85% O(2) demonstrated increased mortality upon withdrawal of doxycycline. CONCLUSIONS: Local expression of SP-D protects against hyperoxic lung injury through modulation of proinflammatory cytokines and antioxidant enzymatic scavenger systems.
Authors: Elena N Atochina; Andrew J Gow; James M Beck; Angela Haczku; Adam Inch; Helchem Kadire; Yaniv Tomer; Christine Davis; Angela M Preston; Francis Poulain; Samuel Hawgood; Michael F Beers Journal: J Infect Dis Date: 2004-03-30 Impact factor: 5.226
Authors: Elena N Atochina; James M Beck; Angela M Preston; Angela Haczku; Yaniv Tomer; Seth T Scanlon; Trevor Fusaro; John Casey; Samuel Hawgood; Andrew J Gow; Michael F Beers Journal: Infect Immun Date: 2004-10 Impact factor: 3.441
Authors: Elena N Atochina-Vasserman; Sandra R Bates; Peggy Zhang; Helen Abramova; Zhenguo Zhang; Linda Gonzales; Jian-Qin Tao; Bernadette R Gochuico; William Gahl; Chang-Jiang Guo; Andrew J Gow; Michael F Beers; Susan Guttentag Journal: Am J Respir Crit Care Med Date: 2011-08-15 Impact factor: 21.405
Authors: Won-Keun Kim; Deepika Jain; Melissa D Sánchez; Cynthia J Koziol-White; Krystal Matthews; Moyar Q Ge; Angela Haczku; Reynold A Panettieri; Matthew B Frieman; Carolina B López Journal: Am J Respir Crit Care Med Date: 2014-02-15 Impact factor: 21.405
Authors: Sang-Min Lee; Joseph N McLaughlin; Daniel R Frederick; Lin Zhu; Kalidasan Thambiayya; Karla J Wasserloos; Iris Kaminski; Linda L Pearce; Jim Peterson; Jin Li; Joseph D Latoche; Octavia M Peck Palmer; Donna Beer Stolz; Cheryl L Fattman; John F Alcorn; Tim D Oury; Derek C Angus; Bruce R Pitt; A Murat Kaynar Journal: Am J Physiol Lung Cell Mol Physiol Date: 2012-12-28 Impact factor: 5.464
Authors: Chang-Jiang Guo; Elena N Atochina-Vasserman; Elena Abramova; Ley Cody Smith; Michael F Beers; Andrew J Gow Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-08-14 Impact factor: 5.464
Authors: Rama Malaviya; Andrew J Gow; Mary Francis; Elena V Abramova; Jeffrey D Laskin; Debra L Laskin Journal: Toxicol Sci Date: 2014-12-30 Impact factor: 4.849